LANCASTER, Calif. -- (BUSINESS WIRE) -- Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that Walt Woltosz, chairman and chief executive officer, will present at the Sidoti & Company Semi-Annual New York Micro-Cap Conference at 11:20 a.m. Eastern Time on Monday, January 7, 2013, in Estate 6 (Uris Room) at the Grand Hyatt New York Hotel.
Simulations Plus management will be available during the day for one-on-one meetings. To schedule a meeting, please contact your Sidoti representative. A copy of the investor presentation that will accompany management’s group presentation will be available at the Simulations Plus corporate website - www.simulations-plus.com - prior to the presentation.
Sidoti & Company, LLC
Sidoti & Company, LLC Micro-Cap Conference is one of the largest micro-cap focused investor events in the U.S., with over 400 institutional investor attendees at the previous micro-cap conference. For more information or to register for the conference, please visit http://microcap.sidoti.com.
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. For more information, please visit www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.